Method for detecting the presence of ring shaped particle tumor marker

A method of purifying a universal tumor marker characterized by ring shaped particles comprising:

• precipitating proteins from serum, wherein the serum is prepared from a patient suffering from cancer, with about 50% (saturation) ammonium sulfate;
• collecting the precipitate;
• dissolving the collected precipitate in a liquid medium;
• applying the dissolved precipitate to a gel filtration medium;
• collecting fractions from the gel filtration medium which bind to tRNA, to form gel filtration purified material;
• applying the gel filtration purified material to a calcium phosphate gel;
• washing the calcium phosphate gel and gel filtration purified material to remove unbound material;
• eluting material from the calcium phosphate gel;
• collecting fractions from the calcium phosphate gel which bind to tRNA, to form calcium phosphate gel purified material;
• binding the calcium phosphate gel purified material to a cibicron blue containing chromatography medium;
• washing the cibicron blue containing chromatography medium and the calcium phosphate gel purified material to remove unbound material;
• eluting material from the cibicron blue containing chromatography medium;
• and
• collecting fractions from the cibicron blue containing chromatography medium which bind tRNA, to form universal tumor marker.

A method of purifying a universal tumor marker characterized by ring shaped particles comprising:

• precipitating proteins from serum, wherein the serum is prepared from of a patient suffering from cancer, with about 50% (saturation) ammonium sulfate;
• collecting the precipitate;
• dissolving the collected precipitate in a buffer comprising about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;
• precipitating proteins from the dissolved precipitate with about 50% (saturation) ammonium sulfate;
• collecting the precipitate;
• dissolving the collected precipitate in a buffer comprising about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;
• applying the dissolved precipitate to a gel filtration medium wherein the gel filtration medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;
• collecting fractions from the gel filtration medium which bind to tRNA, to form gel filtration purified material;
• applying the gel filtration purified material to a calcium phosphate gel wherein the calcium phosphate gel is equilibrated with about 25 mM potassium phosphate, pH 6.8, about 1 mM dithiothreitol and about 20% (v/v) glycerol;
• washing the calcium phosphate gel and gel filtration purified material to remove unbound material;
• eluting material from the calcium phosphate gel with a linear gradient from about 100 to about 150 mM potassium phosphate, pH 6.8, in about 1 mM dithiothreitol and about 20% (v/v) glycerol;
• collecting fractions from the calcium phosphate gel which bind to tRNA, to form calcium phosphate gel purified material;
• binding the calcium phosphate gel purified material to a cibicron blue containing chromatography medium wherein the cibicron blue containing chromatography medium is equilibrated with about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;
• washing the cibicron blue containing chromatography medium and the calcium phosphate gel purified material to remove unbound material;
• eluting material from the cibicron blue containing chromatography medium with a linear gradient from about 0 to about 0.6M potassium chloride in about 50 mM Tris-HCl, pH 7.5, about 1 mM dithiothreitol, about 20% v/v glycerol and about 0.02% w/v sodium azide;
• and
• collecting fractions from the cibicron blue containing chromatography medium which bind tRNA, to form universal tumor marker.